ArticleKidney international reports2026
Equitable Donor Assessment Model of Deceased Donor Kidney Quality.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Kidney Donor Profile Index (KDPI) guides organ allocation but blends donor and recipient influences, potentially misclassifying organ quality and contributing to inequity. We developed the Equitable Donor Assessment Model (EDAM), a donor-focused index that isolates intrinsic graft-failure risk independent of recipient survival. Methods: Using the United Network for Organ Sharing (UNOS) data (2010-2020; Results: Higher donor age, diabetes, hypertension, stroke as cause of death, proteinuria, cytomegalovirus (CMV) seropositivity, and elevated creatinine independently increased graft-failure risk. EDAM demonstrated robust discrimination (C-index = 0.69) and excellent calibration across US regions (pooled slope = 1.02; intercept = -0.002). Stratification into 5 data-driven categories showed a graded rise in cumulative incidence of graft failure (Gray's Conclusion: EDAM provides an equitable, donor-centric framework for assessing kidney quality. Although these categorical thresholds were derived in a data-driven manner within the US system and require external validation in international cohorts, EDAM's ability to safely expand the low-risk pool without compromising outcomes suggests it could significantly refine allocation policy and enhance fairness in kidney transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.